Recently, the 44th Annual J.P. Morgan Healthcare Conference (JPM) concluded in San Francisco. As the “bellwether” and premier stage of the global biopharma industry, the conference gathered top-tier pharmaceutical companies, investment firms, and innovators, focusing on six core pillars including Biotechnology, Biopharma, and AI-driven Medicine.
As a leader in AI-powered drug discovery, XtalPi was invited to participate in this prestigious event. Dr. Jian Ma, Co-founder and CEO of XtalPi, delivered a keynote presentation during the conference, sharing deep insights on how the integration of AI and Robotics is reshaping the drug R&D paradigm.
Reconstructing R&D Logic via AI + Robotics
By combining quantum physics, AI, and robotics, XtalPi has solidified its technological foundation to drive a continuous revolution in drug discovery.
XtalPi’s collaborative ecosystem continues to deliver breakthrough results:
- Signet Therapeutics: SIGX1094 (Diffuse Gastric Cancer) entered Phase I trials; nominated for the 2025 Prix Galien USA and granted FDA Orphan Drug/Fast Track status.
- Leman Pharmaceutics: Ultra-low-dose CAR-T therapy showed superior safety in IIT trials for hematological tumors and autoimmune diseases.
- Revir Therapeutics: RNA-targeted RTX-117 received dual IND clearance from the US FDA and China NMPA.
- PharmaEngine: Next-gen PRMT5 inhibitor PEP08 secured clinical trial approvals in Australia and Taiwan.
Rational Design: Molecular Glues & High-Quality Data
At the Biotech Showcase™ 2026, XtalPi highlighted its Molecular Glue Platform, which replaces traditional stochastic screening with rational design. By integrating physics-based simulations with robotic automation, XtalPi overcomes the “undruggable” challenge with precision.
To support this, XtalPi has built a closed-loop data infrastructure. By automating the “Data – Training – Validation” cycle, the company provides the rigorous, high-fidelity datasets essential for cutting-edge algorithmic breakthroughs.
A Global Innovation Ecosystem
XtalPi continues to foster an open innovation network with elite institutions like Harvard, MIT, and Stanford, incubating a diverse portfolio:
- MorphMind: No-code AI Research Agents for target discovery.
- Foundry Bio: AI-designed proteins for regenerative medicine.
- Specialized Platforms: Including CytoCan (Immune Cytokines), Jikang (GPCR Antibodies), and Xellar (Organ-on-a-Chip + AI).
Internal platforms also reported significant progress: PepiX (Peptide Discovery) now identifies pM-level molecules in months, while XtalSilence (siRNA), X-Buddy (AI Research Assistant) and MirraXinic (PBPK simulation) further optimize the R&D workflow.
Through global collaboration and deep tech integration, XtalPi is building a full-chain ecosystem to deliver transformative solutions for patients worldwide.
